Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be ≥ 18 years of age~* All subjects must have newly diagnosed, histologically proven adenocarcinoma of the rectum~* All subjects must have an abdominal/pelvis computed tomography (CT ) scan or magnetic resonance imaging (MRI) confirming no evidence of distant metastases~* Distal border of tumor \< 12 cm from anal verge~* Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 2~* No prior treatment for LARC however prior treatments for other cancers are acceptable as long as they are considered curative~Exclusion Criteria:~* Subject is an unsuitable candidate for TME surgery~* Subject has received anticancer therapy~* Subject has received prior radiation therapy~* Subject has had major surgery within 28 days prior to the first dose of study drug~* History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- veliparib and capecitabine and radiation (Type: EXPERIMENTAL): Veliparib on days 1-7, capecitabine and radiation on days 1-5

Based on this trial design, predict the completion outcome and termination type (if applicable).